Guselkumab Could Signal New Era in Psoriatic Arthritis

Guselkumab, the first selective IL-23 inhibitor under the trade name 'Tremfya' received Food and Drug Administration (FDA) approval for treating patients with PsA.

. By 2028, Tremfya is expected to net $361m in the US and $577m globally for the indication of PsA.

‘The US F.D.A approved Tremfya for patients with active psoriatic arthritis. It is having a comparable safety profile to IL-17 inhibitors.’
Read More..

Tweet it Now

Tremfya beat out competing IL-23s: AbbVie’s Skyrizi (risankizumab) and SunPharma’s Ilumya/Ilumetri. The selective IL-23 inhibitors represent the most promising pipeline drug class for PsA.

Tiffany Chan, Immunology Analyst at GlobalData, explains: “Tremfya is expected to do well, based on J&J’s previous experience in the disease space marketing Stelara. Since Stelara’s patent is set to expire in 2023 in the US and Japan and in 2024 in the *5EU, it is likely that J&J will be able to preserve its position in the PsA space with Tremfya’s launch.”

Tremfya and the other selective IL-23 inhibitors is likely to also compete with the IL-17 inhibitors, Eli Lilly’s Taltz (ixekizumab) and Novartis’ Cosentyx (secukinumab), as second-line biologics for PsA patients. In head-to-head trials in plaque psoriasis, Tremfya was proven to be superior to Cosentyx but inferior to Taltz in skin clearance, from the IXORA-R and ECLIPSE trials, respectively.

The medication appears to have a comparable safety profile to the IL-17 inhibitors but a better safety profile compared to Stelara, an IL-12 and IL-23 dual inhibitor.

Notably, unlike their IL-17 counterparts, the IL-23 inhibitors are not contraindicated in patients with inflammatory bowel disease, which is a significant co-morbidity for PsA patients. Taken as a whole, Tremfya will pose a formidable challenge to the current marketed therapies.

Psoriatic Arthritis - Types, Causes, Risk Factors, Diagnosis, Treatment, Prevention & Management
Psoriatic arthritis is a kind of autoimmune inflammatory arthritis, which develops in 30 percent of people with the skin condition of psoriasis.

Chan adds: “Several key American patents are set to expire in the next five years, notably Stelara, but also the TNF-inhibitors AbbVie’s Humira and Amgen/Pfizer’s Enbrel, which have been the first line agents for many years.

In the head-to head VOYAGE-2 trial in plaque psoriasis, Tremfya was superior to Humira, measured by the PASI90 criteria.

If similar results were published in head-to-head PsA trials, Tremfya might be able to take patient shares that would have otherwise gone to cheaper anti-TNF biosimilars.”

Source-Medindia